Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.84 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.84 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.84 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.84 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.84 |
| ▸ | PFKP | Q01813 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.84 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.84 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mti-31 SCHEMBL17354025 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Mti-31 SCHEMBL29921552 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL16024023 | 0.95 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL20734874 | 0.92 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL290672 | 0.92 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29353400 | 0.92 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29397309 | 0.92 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL22449928 | 0.92 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29350053 | 0.92 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL1214881 | 0.92 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250334588-A1 | TREATING TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED DISEASES | UNITED STATES GOVERNMENT | 2025-10-30 | — | — | US | claimed |
| US-20250325528-A1 | THERAPEUTIC ROLE OF mTORC1 INHIBITION OF NON-TUMOR CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-23 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2025123147-A1 | TOLERIZING IMMUNOMODULATORY COMBINATION | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2025-06-19 | — | — | WO | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| CN-118879928-B | SSR primer combination for identifying sesbania and application thereof | 中国热带农业科学院湛江实验站 | 2025-04-11 | — | — | CN | claimed |
| WO-2025044844-A1 | COMBINED DRUG OF ESTROGEN PROTEIN TARGETED DEGRADER AND USE THEREOF | 海创药业股份有限公司 | 2025-03-06 | — | — | WO | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2024-04-11 | — | — | US | claimed |
| CN-117729923-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | claimed |
| EP-4288057-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023196676-A1 | TREATING TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| US-11622965-B2 | Methods for treating lymphoid malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2023-04-11 | — | — | US | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | DUSP6, SOS1, DUSP1 | MTOR 25/4885PIK3CA 99/4885PIK3CD 271/4885 |
| US-11622965-B2 | Methods for treating lymphoid malignancies | BTK, BCL6, BCL6B | MTOR 995/4885PIK3CA 322/4885PIK3CD 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.